Welcome to our dedicated page for KESTRA MEDICAL TECHNOLOGIES, LTD. SEC filings (Ticker: KMTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KESTRA MEDICAL TECHNOLOGIES, LTD.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KESTRA MEDICAL TECHNOLOGIES, LTD.'s regulatory disclosures and financial reporting.
Kestra Medical Technologies, Ltd. entered into a five-year senior secured term loan facility of up to $200.0 million with funds managed by Pharmakon Advisors. Tranche A of $75.0 million funded on July 10, 2026, generating approximately $20.0 million of net proceeds after fees and full repayment of the prior Perceptive Credit loan, which was terminated and its security interests released.
The Term Loans mature on July 10, 2031, bear interest at three-month SOFR + 5.50% with a 3.25% SOFR floor, include 48 months of interest-only payments, and then amortize quarterly from the second fiscal quarter of 2030. Covenants include minimum liquidity of at least $20.0 million, limits on additional indebtedness, liens, dividends and mergers, and a security interest over substantially all assets, including intellectual property.
For the quarter ended April 30, 2026, revenue was $28.6 million, up 66% year over year, with gross margin of 54.8%. Fiscal 2026 revenue was $95.1 million, up 59%, with gross margin of 51.4%. GAAP net loss was $131.6 million and adjusted EBITDA loss was $87.0 million. Cash, cash equivalents and investments totaled $262.2 million as of April 30, 2026. The company guides to FY27 revenue of $137 million, implying 44% growth versus FY26.
Kestra Medical Technologies Chief Business Officer Timothy P. Moran acquired additional company stock through an employee purchase plan. He obtained 227 shares of common stock on June 30, 2026 at $21.55 per share under the 2025 Employee Stock Purchase Plan for the January 1–June 30, 2026 period. Following this ESPP purchase, he directly holds 42,488 shares of Kestra Medical Technologies common stock, which the disclosure states includes unvested restricted stock units.
Kestra Medical Technologies director and officer Traci S. Umberger acquired 942 shares of common stock through the company’s Employee Stock Purchase Plan. The shares were purchased for $21.55 per share, equal to 85% of the closing price on June 29, 2026, under a plan exempt under Rule 16b-3.
Following this ESPP purchase for the period from January 1, 2026 through June 30, 2026, Umberger beneficially owns 162,802 shares of Kestra common stock, which the filing notes includes unvested restricted stock units (RSUs).
KESTRA MEDICAL TECHNOLOGIES, LTD. director and officer Brian Daniel Webster reported an open-market sale of 15,000 common shares. The sale was executed at a weighted average price of $20.8095 per share, with individual trade prices ranging from $20.5400 to $21.3900.
After this transaction, Webster directly holds 395,467 common shares. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025, indicating the trades were scheduled in advance rather than timed discretionarily.
Kestra Medical Technologies, Ltd. reported Form 144 filings showing proposed and completed dispositions of 15,000 common shares under an issuer equity compensation plan. The filing lists a restricted share issuance dated 01/21/2026 and multiple sales by Brian Webster of 15,000 shares each on 02/17/2026, 03/17/2026, 04/15/2026 and 05/15/2026, with dollar amounts shown per trade.
Moran Timothy P. reported acquisition or exercise transactions in this Form 4 filing.
Kestra Medical Technologies reported that Chief Business Officer Timothy P. Moran received a grant of 22,704 restricted stock units (RSUs), each representing one common share at settlement. These RSUs vest over three years, with one-third vesting on each anniversary of June 3, 2026, subject to his continued service. Following this award, Moran holds 42,261 common shares directly. This is a compensation-related equity grant rather than an open-market stock purchase or sale.
Ford Alfred J Jr reported acquisition or exercise transactions in this Form 4 filing.
Kestra Medical Technologies Chief Commercial Officer receives equity award. Alfred J. Ford Jr. was granted 25,227 restricted stock units, each representing one common share at settlement and awarded at no cash cost. Subject to continued service, the RSUs will vest over three years, with one-third vesting on each anniversary of June 3, 2026. After this grant, his reported direct holdings total 74,639 common shares or share-equivalent units.
Mahboob Vaseem reported acquisition or exercise transactions in this Form 4 filing.
Kestra Medical Technologies Chief Financial Officer Mahboob Vaseem reported an equity compensation grant in the form of restricted stock units. He was awarded 25,227 RSUs that each entitle him to receive one common share at settlement. Subject to his continued service, one third of these RSUs will vest on each anniversary of June 3, 2026, over a three-year period. Following this grant, he beneficially owns 67,961 common shares, which include 5,837 common shares received in a prior pro rata distribution from West Affum Holdings, L.P. that was exempt under Rule 16a-9.
Umberger Traci S reported acquisition or exercise transactions in this Form 4 filing.
Kestra Medical Technologies director and officer Traci S. Umberger received a grant of 25,227 restricted stock units (RSUs). These RSUs entitle her to one common share per unit upon settlement and will vest over three years, with one-third vesting on each anniversary of June 3, 2026, subject to continued service. Following this equity award, her direct holdings increased to 161,860 common shares, reflecting routine stock-based compensation rather than an open-market purchase or sale.
Webster Brian Daniel reported acquisition or exercise transactions in this Form 4 filing.
Kestra Medical Technologies director and officer Brian Daniel Webster received an equity grant of 75,681 restricted stock units (RSUs), each settling into one common share at no purchase price. These RSUs vest over three years, with one-third vesting on each anniversary of June 3, 2026, contingent on his continued service. Following this grant, Webster is reported as beneficially owning 410,467 common shares, showing his overall equity stake including this new award.